A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in SwedenJ. Andersson, Jonas Bergh, Lena Tennvall-Nittby et al.|Acta Oncologica|2002Cited by 22
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1Paula Poikonen‐Saksela, Johan Ahlgren, Henrik Lindman et al.|Acta Oncologica|2020Cited by 5
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)Henrik Lindman, Carl Blomqvist, Michael Andersson et al.|European Journal of Cancer|2018Cited by 4